Nuclear Medicine Market Analysis

Application (Cardiology, Neurology, Oncology)

The global nuclear medicine market is segmented and analysed fir demand and supply by application into cardiology, neurology, and oncology. Out of which, the oncology segment is anticipated to garner the largest revenue by the end of 2037, backed by growing population who are prone to smoking. According to the World Health Organization, in 2020, 36.7% of all men and 7.8% of all women consumed cigarettes. This represents 22.3% of the world's population. Smoking is the main cause of growing prevalence of cancer all around the world which is further expected to boost the growth of the market. As per the World Health Organization, the use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities.

Our in-depth analysis of the global nuclear medicine market includes the following segments:

By Product	Diagnostic Products Therapeutic Products
By Application	Cardiology Neurology Oncology Lymphoma Bone Metastasis Endocrine Tumor
By End-User	Hospitals & Clinics Diagnostic Centers

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of nuclear medicine is estimated at USD 15.04 billion.

The nuclear medicine market size was over USD 12.94 billion in 2024 and is set to cross USD 143.71 billion by the end of 2037, growing at more than 20.1% CAGR during the forecast period i.e., between 2025-2037. The market growth is driven by growing prevalence of cardiovascular diseases, growing geriatric population, new product launches by key players, and others.

Asia Pacific industry is poised to dominate majority revenue share by 2037, owing to increasing awareness about nuclear medicine and growing investment in nuclear medicine space in the region.

The major players in the market include GE Healthcare, Jubilant Pharmova Limited, Nordion (Canada), Inc., Bracco Imaging S.P.A, The Institute for Radioelements (IRE), NTP Radioisotopes SOC Ltd., The Australian Nuclear Science and Technology Organization (ANSTO), Mallinckrodt Pharmaceuticals, Lantheus, Eckert & Ziegler.

Nuclear Medicine Market Analysis